Allinaire Therapeutics

Executive Summary

Allinaire Therapeutics is a preclinical-stage biopharmaceutical company developing humanized monoclonal antibodies targeting endothelial monocyte activating polypeptide II (EMAP II) for the treatment of pulmonary arterial hypertension (PAH). EMAP II is a non-classical cytokine implicated in apoptosis, endothelial dysfunction, and inflammation, key drivers of PAH pathology. By neutralizing EMAP II, Allinaire's lead candidate aims to modify disease progression rather than just alleviate symptoms, addressing a significant unmet need in a market with limited disease-modifying therapies. The company was founded in 2016 and is based in Cambridge, Massachusetts, with technology licensed from Indiana University.

Upcoming Catalysts (preview)

• Q2 2026Presentation of preclinical efficacy data at ATS 202685% success
• Q4 2026IND filing for lead anti-EMAP II antibody65% success
• Q2 2027Initiation of Phase 1 clinical trial50% success